Date: Sunday, April 30, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
The need for using induction therapy in de novo non-HLA sensitized kidney-transplant patients receiving tacrolimus-based therapy is a matter of debate. The aims of this study were to assess the incidence of donor-specific antibodies (DSAs) and acute rejection in this setting.
All non-HLA sensitized de novo kidney-transplant patients who have received maintenance immunosuppression based on tacrolimus and mycophenolic acid with or without steroids, with or without induction therapy, and who had undergone a first kidney transplantation between Mars 2008 to June 2015 were included in the study (n=450). 325 patients had received induction therapy (281 with basiliximab, and 44 with polyclonal antibodies). The remaining patients did not receive induction therapy (n=125). During the first year posttransplant, the incidence of acute rejection was 10.2% (44 out of 450 patients). Acute rejection episodes occurred in 38 patients who had been given induction therapy (11.7%) and 8 patients who have not be offered induction therapy (6.4%), p=ns. During the first year post-transplant, 9 patients who received induction developed at least one DSA (2.8%) versus none in the group without induction therapy (p=ns). Estimated glomerular filtration rate did not differ between both groups.
In conclusion, induction therapy is not required in low-immunological risk patients given tacrolimus and mycophenolic acid maintenance immunosuppression.
CITATION INFORMATION: Marion O, Del Bello A, Ferrandiz I, Esposito L, Congy N, Hebral A.-L, Kamar N. Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:Marion O, Bello ADel, Ferrandiz I, Esposito L, Congy N, Hebral A-L, Kamar N. Incidence of Acute Rejection and Donor Specific Antibodies in Low-Immunological Risk Patients Treated by Tacrolimus and Mycophenolic Acid with or without Induction Therapy. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-of-acute-rejection-and-donor-specific-antibodies-in-low-immunological-risk-patients-treated-by-tacrolimus-and-mycophenolic-acid-with-or-without-induction-therapy/. Accessed November 23, 2020.
« Back to 2017 American Transplant Congress